Safety Considerations There are currently no published studies specifically examining the combination of CJC-1295 and Tirzepatide in humans
When you give a patient a chemotherapeutic, its kind of an arms race: Youre killing the cancer cells, but youre also killing the rest of the body because so many things are similar
Lindsey Yourman, associate clinical professor in the division of geriatrics, gerontology, and palliative care at the University of California San Diego School of Medicine
The practical implication [of the meeting] is that this is the gatekeeping moment for whether these peptides move from a legal gray zone into legitimate pharmacy compounding. More great longreads: At 75, I'm Rethinking My No Plastic Surgery Stance Why Try to Live to 100 When I Can't Afford Being 32
CagriSema is further along in the approval processNovo Nordisk submitted it to the FDA in December 2025but cagrilintide itself has its own clinical program
and Diaz Perez, J.L., 1994